New drug targets Hard-to-Treat prostate cancer

NCT ID NCT06842498

Recruiting now Disease control Sponsor: Kyntra Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called FG-3246, which is designed to seek out and attack prostate cancer cells that have a specific marker (CD46) on their surface. The study will enroll 75 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. Researchers will monitor safety, how well the drug works, and how long it keeps the cancer from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FG-3246 (a CD46-targeted antibody-drug conjugate)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early Phase 2 trial with only 75 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Bioresearch Partner - Aventura
RECRUITING

Aventura, Florida, 33180, United States
Bioresearch Partner - Hialeah
RECRUITING

Hialeah, Florida, 33013, United States
Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Duke University Medical Center - Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
East Jefferson General Hospital Metairie
RECRUITING

New Orleans, Louisiana, 70112, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
HonorHealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
New Haven Hospital - Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06519, United States
New Mexico Oncology Hematology Consultants, Ltd.
RECRUITING

Albuquerque, New Mexico, 87109, United States

Contact Email: •••••@•••••
Oncology Consultants
RECRUITING

Houston, Texas, 77030, United States
The University of Arizona Cancer Center - North Campus
RECRUITING

Tucson, Arizona, 85719, United States
UCLA Clark Urology Center
RECRUITING

Los Angeles, California, 90095, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94158, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Virginia Comprehensive Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States
University of Washington Medical Center
RECRUITING

Seattle, Washington, 98195, United States
VA Greater Los Angeles Healthcare System
RECRUITING

Los Angeles, California, 90073, United States
Western Regional Medical Center - City of Hope Phoenix Goodyear
RECRUITING

Goodyear, Arizona, 85338, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.